The neurotech investor landscape 2025-2026: Q1 2025 to Q1 2026 funding analysis — $2.36B across 30 deals, 75% BCI
Summary
New Market Pitch published the most comprehensive public analysis of neurotechnology funding from Q1 2025 to Q1 2026: $2.36 billion across 30 publicly disclosed rounds, with brain-computer interface companies capturing ~75% ($1.77B across 11 deals). Q1 2026 was the strongest quarter at $976M — unlike Q2 2025 which was dominated by Neuralink's $650M (86% of that quarter). Only 5 investors appeared in more than one deal, indicating a fragmented investor base. Khosla Ventures was most active (Somnee, Synchron, Science Corp). China-based startups raised $356M+ led by BrainCo ($286M). Average deal size: $79M (heavily influenced by mega-rounds). Neuromodulation attracted the most deals (12 rounds) across migraine, depression, asthma, Tourette, and more.
Why it matters
Five quarters of comprehensive neurotech funding data with source-verified deal information is the most reliable market intelligence dataset for the sector. The fragmented investor base (only 5 investors in more than one deal) is a market structure insight: unlike AI, where a handful of mega-funds dominate every round, neurotech capital formation is diffuse — which means both more competition for founder-friendly terms and more risk of undercapitalization in difficult markets.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial